19-Apr-2024
I-Mab Announces CMO Transition, Interim Successor Named
TipRanks (Mon, 15-Apr 9:03 PM ET)
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
PRNewswire (Sat, 6-Apr 1:05 AM ET)
I-Mab Announces Closing of the Divestiture of Business Operations in China
PRNewswire (Tue, 2-Apr 4:01 PM ET)
I-Mab Reports Full Year 2023 Financial Results and Business Update
PRNewswire (Thu, 14-Mar 5:00 PM ET)
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
PRNewswire (Wed, 7-Feb 6:00 AM ET)
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.
I-Mab - American Depositary Shares trades on the NASDAQ stock market under the symbol IMAB.
As of April 19, 2024, IMAB stock price was flat at $1.80 with 320,248 million shares trading.
IMAB has a beta of 2.59, meaning it tends to be more sensitive to market movements. IMAB has a correlation of 0.15 to the broad based SPY ETF.
IMAB has a market cap of $143.86 million. This is considered a Micro Cap stock.
In the last 3 years, IMAB stock traded as high as $85.40 and as low as $1.16.
The top ETF exchange traded funds that IMAB belongs to (by Net Assets): PGJ, SPEM, GXC, QQQS, EWX.
IMAB stock has underperformed the market in the last year with a return of -47.4%, while SPY returned +21.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in IMAB shares. However, IMAB has outperformed the market in the last 3 month and 2 week periods, returning +11.5% and 0.0%, while SPY returned +4.3% and -3.5%, respectively. This indicates IMAB has been having a stronger performance recently.
IMAB support price is $1.75 and resistance is $1.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMAB stock will trade within this expected range on the day.